Skip to content
Numerate
Numerate
  • COMPANY
  • PROGRAMS
  • PLATFORM
  • CONTACT
  • NEWS
Numerate
  • COMPANY
  • PROGRAMS
  • PLATFORM
  • CONTACT
  • NEWS

Month: December 2013

Numerate receives Wellcome Trust funds to combat Alzheimer’s Disease

December 11, 2013January 25, 2017

Numerate in collaboration with Robert Mahley, MD, PhD, at Gladstone Institute at UCSF, have received a Seeding Drug Discovery Award from the Wellcome Trust to pursue novel Alzheimer’s therapeutics.  Together we will use the funding to identify new chemical compounds that can target apolipoprotein E4 (apoE4) — the strongest genetic risk factor for developing Alzheimer’s.

Archives

  • January 2019
  • September 2018
  • April 2018
  • February 2018
  • November 2017
  • October 2017
  • August 2017
  • June 2017
  • January 2017
  • September 2016
  • September 2015
  • June 2014
  • December 2013
  • August 2013
  • July 2012
  • June 2012
  • March 2012
  • December 2011
  • July 2011
  • June 2011
  • January 2011
  • September 2010
  • August 2010
  • May 2010
  • June 2009

Follow Us

Visit Us On TwitterVisit Us On FacebookVisit Us On Linkedin

News

  • Numerate and Lundbeck Partner to Apply AI Drug Discovery to Unlock Challenges of Neuroscience Research
  • Alliance for Artificial Intelligence in Healthcare (AAIH) Convenes in Boston and Basel to Announce Mission and Launch Activities
  • Numerate to join ATOM Consortium to Rapidly Accelerate Preclinical Drug Development
  • DTRA Renews Contract to Support Continued Development of Numerate’s Predictive Toxicity System

Latest Tweets

My Tweets
© Numerate 2019. All Rights Reserved | Terms of Use | Privacy Policy
NUMERATE, Nu, and DATA DRIVEN DRUG DESIGN are registered trademarks of Numerate, Inc.
All other trademarks are the property of their respective owners.